1. \*\*Radioligand (choose only one):

[ ]  Ioflupane

[ ]  IACFT

[ ]  β-CIT

[ ]  FDG

[ ]  Florbetapir

[ ]  Florbetaben

[ ]  PIB

[ ]  DOPA

[ ]  MIBG

[ ]  Fluoro-metatyrosine (FMT)

[ ]  DTBZ, specify:

[ ]  Other, specify:

1. \*\*Specific activity of radioligand:

[ ]  (Bq/kg):

[ ]  Not Known

1. \*\*Isotope:

[ ]  123-I

[ ]  18-F

[ ]  11-C

[ ]  99 Tcm

[ ]  Other, specify:

1. \*\*Camera :

[ ]  PET/CT

[ ]  PET MRI

[ ]  PET

[ ]  SPECT

[ ]  SPECT/CT

[ ]  Other, specify:

1. \*\*Scanner (include Model and Manufacturer):

[ ]  Siemens

Model:

[ ]  Philips

Model:

[ ]  GE

Model:

[ ]  Other, specify:

Model:

1. \*\*Camera Software:
2. \*\*Dose:

[ ]  mCi

[ ]  Mbq

[ ]  Other, specify:

1. \*\*Time from Injection to Scan (minutes):
2. \*\*Duration of Scan (minutes):
3. \*\*Image Matrix Size:

[ ]  64 X 64

[ ]  128 X 128

[ ]  512 X 512

[ ]  Other, specify:

1. \*\*Slice Thickness (mm):
2. \*\*Pre-Scan Action(s):

[ ]  Lugols

[ ]  Perchlorate

[ ]  Limit sensory stimulation

[ ]  Carbidopa, specify:

[ ]  Other, specify:

1. \*\*Time of Scan Initiation:
2. \*\*PD Medications: [ ]  Yes [ ]  No

\*\*If YES, list the last dose of PD medications:

**Table 3: Medication Timing**

| Parkinson’s Disease (PD) Medication | Time of Last Dose |
| --- | --- |
| Data to be filled in by site | Data to be filled in by site |
| Data to be filled in by site | Data to be filled in by site |
| Data to be filled in by site | Data to be filled in by site |
| Data to be filled in by site | Data to be filled in by site |

1. \*\*Current Body Weight (kg):
2. \*\*Status of participant during scan:

[ ]  Directly observed

[ ]  Movements recorded

1. \*\*Post Injection Management Prior to Scan:

[ ]  No special management required

[ ]  Quiet room

[ ]  Eyes open

[ ]  Other, specify:

1. \*\*Reconstruction of Raw Data:

[ ]  Iterative [ ]  Filtered back projection [ ]  Other, specify:

1. \*\*Attenuation Correction:

[ ]  Homogenous

[ ]  Inhomogenous

[ ]  Other, specify:

1. \*\*Scatter Correction: [ ]  Yes [ ]  No
2. \*\*Deadtime Correction: [ ]  Yes [ ]  No
3. \*\*Randoms Correction: [ ]  Yes [ ]  No
4. \*\*Post Reconstruction Filter:

[ ]  Butterworth

[ ]  Lowpass

1. \*\*Reconstructed Image Resolution (FWHM):
2. \*\*Visual Analysis:

[ ]  Normal

[ ]  Abnormal

[ ]  Other, specify:

1. \*\*Where visual analysis was performed:

[ ]  Site

[ ]  Central

[ ]  Other, specify:

1. \*\*Was the visual analysis performed blinded to clinical data?

[ ]  Yes

[ ]  No

[ ]  Unknown

[ ]  Other, specify:

1. \*\*Imaging Outcome:

[ ]  Volume of interest

[ ]  Voxel based

[ ]  Other, specify:

1. \*\*Method for VOI Placement:

[ ]  Automated

[ ]  Subjective Placement

[ ]  Other, specify:

1. \*\*VOI Locations:

[ ]  Striatum

[ ]  Cortex

[ ]  Other, specify:

1. \*\*Reference Region:
2. \*\*MRI Acquired for Co-registration: [ ]  Yes [ ]  No
	1. If YES, date of MRI acquisition (mm/dd/yyyy)
3. Quantitative Imaging Outcome: [ ]  Yes [ ]  No

If YES, indicate type:

[ ]  DAT

[ ]  Ioflupane (SPECT)

[ ]  IACFT (SPECT)

[ ]  β-CIT

[ ]  CFT (PET)

[ ]  VMAT2

[ ]  AV133

[ ]  DTBZ

[ ]  Tyrosine Hydroxylase

[ ]  Fluoro-metatyrosine (FMT)

[ ]  FDopa

[ ]  Striatal (Regional) Binding Ratios

[ ]  Putamen Binding Ratio

[ ]  Caudate Binding Ratio

[ ]  Other, specify:

[ ]  Amyloid Imaging Standard Uptake Value (SUV)

[ ]  Amyloid Imaging Binding Potential

[ ]  Amyloid Imaging Volume of Distribution

[ ]  Amyloid Imaging Mean Cortical Binding Potential

[ ]  Amyloid Imaging Centiloids

[ ]  Neocortex

[ ]  Posterior cingulate/precuneus

[ ]  Frontal

[ ]  Parietal

[ ]  Lateral

[ ]  Temporal

[ ]  Mesiotemporal

[ ]  Anterior cingulate

[ ]  Striatum

[ ]  Cerebellar gray

[ ]  Whole cerebellum

[ ]  Other, specify:

[ ]  Scan aborted, if checked, explain why:

[ ]  Other, specify:

General Instructions

This CRF contains data that would be collected when an imaging study is performed to measure cellular/tissue change. The data recorded assess the rate of absorption of radionuclides in healthy and diseased tissue, as tissue undergoing a disease process will absorb at a different rate.

Important note: None of the data elements included on this CRF Module are classified as Core (i.e., strongly recommended for all Parkinson’s disease clinical studies to collect). Most of the data elements are classified as Supplemental – Highly Recommended, as indicated by asterisks below, and should be collected if imaging studies are performed.

\*\*Element is classified as Supplemental – Highly Recommended

Quantitative imaging outcome is classified as Supplemental and should only be collected if the research team considers this appropriate for their study. Please see the Data Dictionary for element classifications.

Specific Instructions

Please see the Data Dictionary for definitions for each of the data elements included in this CRF Module.